Fifty-three percent. That's the share of employers with more than a hundred workers that still cover GLP-1s for weight loss, according to a new benefits survey. A year ago it was fifty-seven. It's Wednesday, October 28, and you're listening to GLP-1 Daily. That employer pullback is our lead. Next, Walgreens offers to do the prior-authorization legwork, and then a drugmaker says its pill cut the vomiting that pushes some patients off semaglutide.
Cheryl Winokur Munk, writing for CNBC:
A WTW annual health benefits survey fielded over the summer and being released in full on Wednesday found that 53% of employers with more than 100 employees cover GLP-1s for weight loss, down from 57% in 2025. That's the first decline in three years. What's more, 16% of employers said they cover the drugs now but are considering removing them, up from 9% last year.
So the full survey lands today, and CNBC got an early look on Tuesday. The money behind it: employers typically pay somewhere in the mid five hundreds to mid six hundreds of dollars per user per month. A Marsh survey of more than eighteen hundred employers expects per-employee health costs to climb 8.2 percent in 2027, the biggest jump since 2003, with GLP-1s accounting for a full point of that. What replaces coverage varies. Some employers point workers to the drugmakers' own cash programs. Gallagher's Seth Friedman estimates twenty to thirty percent of the firm's clients dropped coverage for 2027 and are sending people that route. Today's cash prices for the lowest doses: a hundred forty-nine dollars a month for the Wegovy pill, a hundred ninety-nine for the shot, and two ninety-nine for Zepbound. Novo says its promotional pricing could change or end. Then there's the consolation prize. Weight-management programs from vendors like Noom, Omada and CVS. The success numbers CNBC cites come from those companies themselves, so treat them as company-reported. And Gallagher's Friedman says getting employees to use them can be a challenge when they can just have a doctor write a script and buy direct. This is the same pattern we covered with Walmart on October 14 and Mass General Brigham last Friday: diabetes coverage stays, weight-loss coverage goes. One practical note from the piece. GLP-1s prescribed for a diagnosed condition, obesity included, can be paid for with FSA or HSA money. Notice who that helps, though. A cash price plus a tax account works if you have the cash. If your plan is changing in January, check during open enrollment what you'd actually pay each month, and talk with your prescriber now rather than when the pen runs out.
Luke Halpern, associate editor at Pharmacy Times:
Walgreens is expanding its weight management services to help eligible patients navigate coverage for glucagon-like peptide-1 (GLP-1) receptor agonists prescribed for weight loss. The additions include virtual care support for commercial insurance checks, prior authorization (PA), and the Medicare GLP-1 Bridge program, as well as pharmacist outreach after prescription pickup for patients who start filling a GLP-1.
Walgreens announced this Tuesday. A virtual visit with a doctor or nurse practitioner costs forty-nine dollars, and the medication isn't included. Virtual weight management isn't offered in Alabama, and for Bridge patients there's a longer list of exclusions, among them Delaware, Kansas, Louisiana, Mississippi and D.C. A reminder on the Bridge itself. It's a CMS demonstration that runs from July 2026 through December 2027, outside the regular Part D benefit, with a fifty-dollar monthly copay. It covers Wegovy shots and tablets, the Zepbound KwikPen, and Foundayo tablets. People with type 2 diabetes, moderate-to-severe sleep apnea and some other conditions are excluded and stay on regular Part D. And here's the detail I'd want every Medicare patient to hear. The first Bridge claim is expected to be rejected, because that rejection is what kicks off the prior auth. A denial on day one doesn't automatically mean you aren't covered. This is a company announcement, so it tells us what Walgreens is offering, not how well it works. Pharmacy Times adds a caution: Congress hasn't changed the law excluding obesity drugs from Part D, so Bridge patients should plan now for the December 2027 end date. Ask your prescriber what your plan looks like after that.
Abigail Brooks, writing for HCPLive:
All participants received a single 1 mg dose of semaglutide without the gradual titration used in clinical practice. Vanda described this as a highly emetogenic test condition.
Translation: they gave people a dose designed to make them throw up, then tested whether a pill could stop it. The pill is tradipitant, sold as Nereus, already FDA-approved since December 2025 for motion-induced vomiting. Vanda announced the phase 3 results Tuesday. The numbers, which are company-reported from a press release, not a peer-reviewed paper: 306 participants. Any vomiting hit 43 percent on tradipitant versus 58.5 percent on placebo, a 27 percent relative reduction. Vomiting plus severe nausea was 33 versus about 51 percent. Vanda says the drug was generally well tolerated with no new safety signals. The really dramatic figures, an eighty-one percent drop in extreme vomiting, come from analyses Vanda itself labels post hoc and exploratory. Pretty headline, weaker evidence. Why it matters anyway: in a large study of more than a hundred twenty-five thousand adults, more than half stopped their GLP-1 within a year, and stomach side effects were tied to stopping. That's the same figure Walgreens cites. But a single untitrated dose isn't how anyone actually starts semaglutide. Vanda plans to meet the FDA in 2027 before filing for this use, so it's not available for GLP-1 nausea now. If side effects are making you think about quitting, say so to your prescriber. There are usually options to discuss before you stop.
Is your employer dropping weight-loss coverage for 2027, or swapping in a reimbursement plan or a coaching app? Tell us what your open-enrollment packet actually says. Email glp1daily at lantern podcasts dot com.
CNBC, Pharmacy Times and HCPLive are in the show notes, and nothing here replaces a conversation with your own clinician. GLP-1 Daily returns tomorrow, Thursday, as part of Lantern Podcasts.